Back to Results
First PageMeta Content
Gene delivery / Medical genetics / Medical research / Molecular biology / Gene therapy / Sofinnova / Blindness / RPE65 / Retina / Biology / Medicine / Emerging technologies


Media Inquiries: Jessica Rowlands[removed]removed] Spark Therapeutics Raises $72.8 Million in Oversubscribed Financing
Add to Reading List

Document Date: 2014-05-27 14:36:51

Open Document

File Size: 106,51 KB

Share Result on Facebook

City

PHILADELPHIA / /

Company

Deerfield Management Company / Rock Springs Capital / Brookside Capital / Spark Therapeutics / The Children's Hospital / T. Rowe Price Associates Inc. / Wellington Management Company LLP / Sofinnova Ventures / /

Country

United States / /

Currency

USD / /

/

Event

FDA Phase / Funding / /

Facility

The Children's Hospital of Philadelphia / Children’s Hospital of Philadelphia / /

IndustryTerm

manufacturing facility / undisclosed dedicated healthcare funds / treatment of debilitating diseases / gene therapy products / manufacturing platform / /

MedicalCondition

RPE65-related blindness / rare diseases / hematological disorders / rare disease / RPE65-related blindness PHILADELPHIA / diseases / blindness / /

MedicalTreatment

Gene therapy / /

Organization

Children's Hospital of Philadelphia / FDA / Children’s Hospital of Philadelphia / /

Person

Jeffrey D. Marrazzo / Anand Mehra / Steven M. Altschuler / Jessica Rowlands / /

/

Position

CEO / leader / General Partner / cofounder / co-founder and CEO / Oversubscribed Financing Gene therapy leader / Chairman of the Board / /

Product

Phase 3 / RPE65 / /

ProvinceOrState

Pennsylvania / /

Technology

Gene therapy / /

URL

www.sparktx.com / /

SocialTag